Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth

Cancer Letters

Volumn 198, Issue 1, 2003, Pages 107-117

  Hirama, Michihiro ^a   Takahashi, Fumiyuki ^a,b   Takahashi, Kazuhisa ^a   Akutagawa, Shigeru ^b   Shimizu, Kazue ^a   Soma, Sanae ^a   Shimanuki, Yuri ^a   Nishio, Kazuto ^b   Fukuchi, Yoshinosuke ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Angiogenesis; Osteopontin; Tumorigenesis

Indexed keywords

ANGIOGENIC FACTOR; CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; CD31 ANTIGEN; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; MATRIGEL; MATRIX METALLOPROTEINASE 14; OSTEOPONTIN; PROTEINASE; UROKINASE; SIALOGLYCOPROTEIN; SPP1 PROTEIN, HUMAN; SPP1 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR CELL; TUMOR GROWTH; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; GENETICS; NEUROBLASTOMA;

MURINAE; MUS MUSCULUS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; CELL DIVISION; FEMALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; OSTEOPONTIN; SIALOGLYCOPROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0142026839     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00286-6     Document Type: Article

References (38)

1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue G.H.A. Clowes memorial Award lecture. Cancer Res. 46:1986;467-473.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82:1990;4-6.
3. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8.
4. Denhardt D.T., Guo X. Osteopontin: a protein with diverse functions. Faseb J. 7:1993;1475-1482.
5. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., Cantor H. Eta-l (osteopontin): an early component of type-l (cell-mediated) immunity. Science. 287:2000;860-864.
6. Takahashi F., Takahashi K., Maeda K., Tominaga S., Fukuchi Y. Osteopontin is induced by nitric oxide in RAW 264.7 cells. IUBMB Life. 49:2000;217-221.
7. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107:2001;1055-1061.
8. Takahashi F., Takahashi K., Okazaki T., Maeda K., Ienaga H., Maeda M., Ken T., Uede Y. Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 24:2001;264-271.
9. Takahashi K., Takahashi F., Tanabe K.K., Takahashi H., Fukuchi Y. The carboxyl-terminal fragment of osteopontin suppresses arginine-glycine-asparatic acid-dependent cell adhesion. Biochem. Mol. Biol. Int. 46:1998;1081-1092.
10. Zhang J., Takahashi K., Takahashi F., Shimizu K., Ohshita F., Kameda Y., Maeda K., Nishio K., Fukuchi Y. Differential osteopontin expression in lung cancer. Cancer Lett. 171:2001;215-222.
11. Tuck A.B., O'Malley F.P., Singhal H., Tonkin K.S., Harris J.F., Bautista D., Chambers F. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch. Pathol. Lab. Med. 121:1997;578-584.
12. Casson A.G., Wilson S.M., McCart J.A., O'Malley F.P., Ozcelik H., Tsao M.S., Chambers A.F. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int. J. Cancer. 72:1997;739-745.
13. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int. J. Cancer. 79:1998;127-132.
14. Gotoh M., Sakamoto M., Kanetaka K., Chuuma M., Hirohashi S. Overexpression of osteopontin in hepatocellular carcinoma. Pathol. Int. 52:2002;19-24.
15. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., MarkwaIder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 5:1999;2271-2277.
16. Agrawal D., Chen T., Irby R., Quackenbush J., Chambers A.F., Szabo M., Cantor A., Coppola D., Yeatman T.J. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst. 94:2002;513-521.
17. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., Berkowitz R.S., Cramer D.W., Mok S.C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama. 287:2002;1671-1679.
18. Behrend E.I., Craig A.M., Wilson S.M., Denhardt D.T., Chambers A.F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res. 54:1994;832-837.
19. Tuck A.B., Arsenault D.M., O'Malley F.P., Hota C., Ling M.C., Wilson S.M., Chambers A.F. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene. 18:1999;4237-4246.
20. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276:2001;44926-44935.
21. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149:1996;293-305.
22. Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer. 82:2000;1967-1973.
23. Shijubo N., Uede T., Ken S., Maeda M., Segawa T., Imada A., Hirasawa M., Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 160:1999;1269-1273.
24. Takahashi F., Akutagawa S., Fukumoto H., Tsukiyama S., Ohe Y., Takahashi K., Fukuchi Y., Saijo N., Nishio K. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int. J. Cancer. 98:2002;707-712.
25. Karasuyama H., Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:1988;97-104.
26. Feigner P.L., Gadek T.R., Holm M., Roman R., Chart H.W., Wenz M., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl Acad. Sci. USA. 84:1987;7413-7417.
27. Enomoto A., Kate K., Yagita H., Okumura K. Adoptive transfer of cytotoxic T lymphocytes induced by CD86- transfected tumor cells suppresses multi-organ metastases of Cl300 neuroblastoma in mice. Cancer Immunol. Immunother. 44:1997;204-210.
28. Natsume T., Koh Y., Kobayashi M., Fukumoto H., Takahashi F., Nakamura T., Ghe Y., Saijo N., Nishio K. Enhanced antitumor activities of TZT-1027 against TNF-alpha or IL-6 secreting Lewis lung carcinoma in viva. Cancer Chemother. Pharmacol. 49:2002;35-47.
29. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143:1993;401-409.
30. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J. Cell Physiol. 182:2000;311-322.
31. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:1992;493-501.
32. Furumatsu T., Nishida K., Kawai A., Namba M., Inoue H., Ninomiya Y. Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. Int. J. Cancer. 97:2002;313-322.
33. Takahashi K., Eto H., Tanabe K. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int. J. Cancer. 80:1999;387-395.
34. Tsunoda T., Nakamura T., Ishimoto K., Yamaue H., Tanimura H., Saijo N., Nishio K. Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. Anticancer Res. 21:2001;137-143.
35. Furger K.A., Menon R.K., Tuckl A.B., Bramwelll V.H., Chambers A.F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med. 1:2001;621-632.
36. Guo H., Cai C.Q., Schroeder R.A., Kuo P.C. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J. Immunol. 166:2001;1079-1086.
37. Scott J.A., Weir M.L., Wilson S.M., Xuan J.W., Chambers A.F., McCormack D.G. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am. J. Physiol. 275:1998;H2258-H2265.
38. Rollo E.E., Laskin D.L., Denhardt T. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J. Leukoc. Biol. 60:1996;397-404.